Detecting and identifying the complexation of nimodipine with hydroxypropyl-β-cyclodextrin present in tablets by Raman spectroscopy

Journal of Pharmaceutical Sciences

Volumn 97, Issue 7, 2008, Pages 2702-2719

  Yang, Xinghao ^a   Ke, Weizhong ^a   Zi, Peng ^a   Liu, Fei ^a   Yu, Lili ^a  

^a NANJING NORMAL UNIVERSITY   (China)

Author keywords

Complexation; HP CD; Nimodipine; Raman spectroscopy; Tablet

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; NIMODIPINE;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DRUG FORMULATION; DRUG STRUCTURE; INFRARED SPECTROSCOPY; RAMAN SPECTROMETRY; TABLET;

EID: 52449112070     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21204     Document Type: Article

References (45)

1. Rajewski R, Stella VJ. 1996. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J Pharm Sci 85:1142-1168.
2. Loftsson T, Brewster ME. 1996. Pharmaceutical application of cyclodextrins. 1. Drug solubilization and stabilisation. J Pharm Sci 85:1017-1025.
3. Veiga F, Teixeira-Dias JJC, Kedzierewicz F, Sousa A, Maincent P. 1996. Inclusion complexation of tolbutamide with β-cyclodextrin and hydroxypropyl-β-cyclodextrin. Int J Pharm 129:63-71.
4. Islam MS, Narurkar MM. 1991. The effect of 2-hydroxypropyl-β- cyclodextrin on the solubility, stability, and dissolution rate of famotidine. Drug Dev Ind Pharm 17:1229-1239.
5. Lin SZ, Wouessidjewe D. 1991. Indomethacin and cyclodextrin complexes. Int J Pharm 69:211-219.
6. Koester LS, Ortega GG, Mayorga P, Bassani VL. 2004. Mathematical evaluation of in vitro release profiles of hydroxypropylmethylcellulose matrix tablets containing carbamazepine associated to β-cyclodextrin. Eur J Pharm Biopharm 58:177-179.
7. Yoshida A, Yamamoto M, Itoh T, Irie T, Hirayama F, Uekama K. 1990. Utility of HP-beta-CD in an intramuscular injectable preparation of nimodi-pine. Chem Pharm Bull 38:176-179.
8. Savolainen J, Jarvinen K, Taipale H, Jarho P, Loftsson T, Jarvinen T. 1998. Co-administration of a water-soluble polymer increases the usefulness of cyclodextrins in solid oral dosage forms. Pharm Res 15:1696-1701.
9. Morris KR, Griesser UJ, Eckhardt CJ, Stowell JG. 2001. Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes. Adv Drug Deliv Rev 48:91-114.
10. Bugay DE. 2001. Characterization of the solid-state: Spectroscopic techniques. Adv Drug Deliv Rev 48:43-65.
11. Atwood JL, Davies JED, Macnicol DD, Vogtle F. 1996. Cyclodextrins. In: Szejtli J, Osa T, editors. Comprehensive supramolecular chemistry cyclodextrins, Vol. 3. Amsterdam: Elsevier. pp. 6-32.
12. Taylor LS, Langkilde FW. 2000. Evaluation of solid-state forms present in tablets by Raman spectroscopy. J Pharm Sci 89:1342-1353.
13. Lombardi DR, Wang C, Sun B, Fountain AW, Vickers TJ, Mann CK, Reich FR, Douglas JG, Crawford BA, Kohlasch FL. 1994. Quantitative and qualitative analysis of some inorganic compounds by Raman spectroscopy. Appl Spectrosc 48:875-883.
14. Pelletier MJ. 2003. Quantitative analysis using Raman spectrometry. Appl Spectrosc 57:20A-42A.
15. Langkilde FW, Sjoblom J, Tekenbergse-Hjelte L, Mrak J. 1997. Quantitative FT-Raman analysis of two crystal form of a pharmaceutical compound. J Pharm Biomed Anal 15:687-696.
16. Findlay WP, Bugay DE. 1998. Utilization of Fourier transform-Raman spectroscopy for the study of pharmaceutical crystal forms. J Pharm Biomed Anal 16:921-930.
17. Vergote GJ, De Beer TRM, Vervaet C, Remon JP, Baeyens WRG, Diericx N, Verpoort F. 2004. In-line monitoring of a pharmaceutical blending process using FT-Raman spectroscopy. Eur J Pharm Sci 21:479-485.
18. Spivey R, Swofford RL. 1999. Inclusion complexes of N-benzoyl-D-leucine and N-benzoyl-L-leucine with beta-cyclodextrin by Raman spectroscopy. Appl Spectrosc 53:435-438.
19. Lamcharfi E, Kunesch G, Meyer C, Robert B. 1995. Investigation of cyclodextrin inclusion compounds using FT-IR and Raman spectroscopy. Spectrochim Acta Part A 51:1861-1870.
20. Ribeiro-Claro PJA, Amado AM, Teixeira-Dias JJC. 1996. Substituted styrene molecules included in cyclodextrins: A Raman Spectroscopic Study. Part II. J Raman Spectrosc 27:155-161.
21. Amado AM, Ribeiro-Claro PJA. 2000. Selection of substituted benzaldehyde conformers by the cyclodextrin inclusion process: A Raman spectroscopic study. J Raman Spectrosc 31:971-978.
22. Ribeiro-Claro PJA, Costa AM, Vueba ML, Pina ME, Amado AM. 2006. Para-halogenated benzaldehyde molecules included in cyclodextrins: A combined spectroscopic and thermal analysis. J Raman Spectrosc 37:472-479.
23. 13C-NMR investigation of the structure of the 1:1 amorphous piroxicam: β-cyclodextrin inclusion compound. Biospectroscopy 4:243-251.
24. Iliescu T, Baia M, Miclaus V. 2004. A Raman spectroscopic study of the diclofenac sodium-β-cyclodextrin interaction. Eur J Pharm Sci 22:487-495.
25. Manhold R. 1985. Nimodipine. Drugs Today 21: 533-536.
26. Kopecky F, Kopecka B, Kaclik C. 2003. Dissolution of nimodipine in an aqueous solution of hydroxyethyl-beta-cyclodextrin and a review of solubility of nimodipine with cyclodextrins. Ceska Slov Farm 52:33-38.
27. Mielcarek J. 1998. Analytical study of photodegradation of inclusion complexes of nimodipine with alpha-, gamma-cyclodextrin, methyl-beta- cyclodextrin, and hydroxypropyl-beta-Cyclodextrin. Drug Dev Ind Pharm 24:197-200.
28. Chowdary KPR, Kamalakara Reddy G. 2001. Investigation of complexation of nimodipine with beta-and hydroxypropyl-beta-cyclodextrins. Indian Drugs 38:555-558.
29. Yu LL. 2005. The preparation and characterization of drug/cyclodextrin supramolecule. Ph.M Thesis, Nanjing Normal University, PR China.
30. Grunenberg A, Keil B, Henck JO. 1995. The polymorphism in binary mixture, as exemplified by nimodipine. Int J Pharm 118:11-21.
31. Giordano F, Novak C, Moyano JR. 2001. Thermal analysis of cyclodextrins and their inclusion compounds. Thermochimica Acta 380:123-151.
32. Uekama K, Narisawa S, Hirayama F, Otagiri M. 1983. Improvement of dissolution and absorption characteristics of benzodiazepines by cyclodextrin complexation. Int J Pharm 16:327-338.
33. Suihko E, Korhonen O, Jarvinen T, Ketolainen J, Jarho P, Laine E, Paronen P. 2001. Complexation with tolbutamide modifies the physicochemical and tableting properties of hydroxypropyl-β-cyclodextrin. Int J Pharm 215:137-145.
34. Vinogradov SN, Linnell RH. 1971. Hydrogen bonding. New York: Van Nostrand Reinhold.
35. Rossi B, Verrocchio P, Viliani G. 2006. Vibrational properties of inclusion complexes: The case of indomethacin-cyclodextrin. J Chem Phys 125:044511-1-044511-7.
36. Bell SEJ, Beattie JR, McGarvey JJ, Peters KL, Sirimuthu1 NMS, Speers SJ. 2004. Development of sampling methods for Raman analysis of solid dosage forms of therapeutic and illicit drugs. J Raman Spectrosc 35:409-417.
37. Wang C, Vickers TJ, Mann CK. 1997. Direct assay and shelf-life monitoring of aspirin tablets using Raman spectroscopy. J Pharm Biomed Anal 16: 87-94.
38. Johansson J, Pettersson S, Folestad S. 2005. Characterization of different laser irradiation methods for quantitative Raman tablet assessment. J Pharm Biomed Anal 39:510-516.
39. Qureshi SA, McGilveray IJ. 1999. Typical variability in drug dissolution testing: Study with USP and FDA calibrator tablets and a marketed drug (glibenclamide) product. Eur J Pharm Sci 7:249-258.
40. He ZG, Zhong DF, Chen XY, Liu XH, Tang X, Zhao LM. 2004. Development of a dissolution medium for nimodipine tablets based on bioavailability evaluation. Eur J Pharm Sci 21:487-491.
41. Swanepoel E, Liebenberg W, Devarakonda B, Villiers MM. 2003. Developing a discriminating dissolution test for three mebendazole polymorphs based on solubility differences. Pharmazie 58:117-121.
42. Veiga MD, Ahsan F. 2000. Influence of surfactants (present in the dissolution media) on the release behavior of tolbutamide from its inclusion complex with β-cyclodextrin. Eur J Pharm Sci 9:291-299.
43. Uekama K, Narisawa S, Hirayama F, Otagiri M. 1983. Improvement of dissolution and absorption characteristics of benzodiazepines by cyclodextrin complexation. Int J Pharm 16:327-338.
44. Erden N, Celebi N. 1988. A study of inclusion complex of naproxen with β-cyclodextrin. Int J Pharm 48:83-89.
45. Vankeirsbilck T, Vercauteren A, Baeyens W, Van der Weken G, Verpoort F, Vergote G, Remon JP. 2002. Applications of Raman spectroscopy in pharmaceutical analysis. Trends Anal Chem 21:869-877.